| Hans-Günter Meyer-Thompson | Buprenorphin
USA/Buprenorphin. FDA Panel Backs New Drug for Opioid Use Disorder
USA/Buprenorphin. FDA Panel Backs New Drug for Opioid Use Disorder
The US Food and Drug Administration's (FDA's) Psychopharmacologic Drugs Advisory Committee has voted 18 to 1 to recommend approval of an investigational drug for the treatment of opioid use disorder (OUD).
RBP-6000 (Indivior PLC) is a once-monthly injectable formulation of buprenorphine that uses the Atrigel delivery system for the treatment of adults with moderate to severe OUD as part of a complete treatment plan that includes counseling and psychosocial support, the company said in a news release. (Medscape, 01.11.2017)